Investor Presentation

Here is the summary: **Financial Highlights:** Anthem Biosciences reported strong Q1FY26 results: Revenue up 59.5% YoY to ₹540.2 Cr, led by CRDMO (₹452.7 Cr, up 70.5%). EBITDA grew 52.7% to ₹214.3 Cr (38.1% margin). PAT jumped 64.8% to ₹135.8 Cr (24.1% margin). Net cash: ₹784.8 Cr. **Strategic Initiatives & Growth Drivers:** Major capacity expansion underway: Unit II commissioned 54 kL custom synthesis.

Unit III launched phased operations, adding new peptide (16kL) and hi-potent (2.5kL) manufacturing.

Ground broken for greenfield Unit IV on 30 acres. **Business Developments:** Operational highlights include Unit II's expanded custom synthesis and Unit III's specialized manufacturing facilities commencing.

Unit IV construction is underway, signaling continuous scale-up. **Market Position & Competitive Advantage:** Performance driven by robust technology, infrastructure (324KL Custom Synthesis, 142KL Fermentation), and a strong balance sheet.

Dedicated team and client partnerships enhance competitive edge. **Investor Implications:** Strong Q1FY26 financials and aggressive capacity additions signal positive growth potential.

Company is actively investing to meet future demand and solidify market leadership.